By now most biotech investors know about RNAi companies like Alnylam Pharmaceuticals (ALNY) and Isis Pharmaceuticals (ISIS), and many probably know Tekmira (TKMR) and Arrowhead Research (ARWR)
as well. Alnylam and Isis have excited investors with the potential
multiple billion-dollar drugs in their pipeline, while Tekmira and
Arrowhead have solid delivery technologies and emerging therapeutic
pipelines.
If you'll pardon the obvious pun, it has been a lot quieter where London-based Silence Therapeutics (OTCPK:SLNCF)
(SLN.L) is concerned. This small biotech is barely followed on the
Street and isn't exceedingly liquid even on its home stock exchange (the
LSE). Silence's corporate history is shakier than many others and the
company does not have a particularly thick book of clinical data in
humans, but what the company does have is a three-pronged delivery
platform that could, like Arrowhead's delivery technology, open up a
wider range of treatment targets for RNAi therapy.
Read the full article here:
Silence Therapeutics A Quieter Name In RNAi
No comments:
Post a Comment